Enjoy complimentary customisation on priority with our Enterprise License!
Extensive research carried out by the analysts at Technavio has shown that the global hypertension drugs market will post an impressive market value of USD 32 billion by the end of 2020. With an increase in the population of older people, the market for hypertension drugs has a positive outlook over the forecast period. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Since the risk of developing pulmonary hypertension increases with age, a growing older population will aid in the growth prospects of the hypertension drugs market size in the coming years.
In this industry research report, the analysts have estimated factors like the growing awareness of hypertension and it's treatment options to impel this market’s growth prospects until the end of 2020. Enhanced patient awareness results in an early diagnosis of the disease followed by treatment. For instance, the National Heart, Lung, and Blood Institute of National Institutes of Health launched the High Blood Pressure Education program which is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to hypertension through several professional programs, patient interaction, and public education. Similarly, 17th May is celebrated as the World Hypertension Day every year by the International Society of Hypertension. Such events and resources increase awareness among people and are expected to drive the market growth for hypertension drugs during the forecast period.
During 2015, the systemic hypertension drugs segment dominated the hypertension drugs market and accounted for close to 87% of the market share. However, the market segment is expected to witness a decline in the forecast period because of patent expiries of drugs, followed by generic erosion. The systemic hypertension drugs market is expected to reach more than USD 27 billion by the end of 2020.
In 2015, the Americas was the largest market for hypertension drugs as it accounted for more than 44% of the market share. The US is the major revenue contributor in the region. The market share is declining due to the patent expiries of drugs such as Micardis, Avapro, and Diovan. However, comorbid conditions among the older population like congenital heart disease and increasing focus on combination therapies will prevent the decline in the market. Moreover, the launch of new disease-modifying therapies is expected to bolster the growth prospects of the market during the forecast period.
The global market for the hypertension drugs is high consolidated due to the presence of a few well-established vendors. At present, the market is declining because of the increased use of generic drugs. Therefore, companies are investing heavily in the development of new medicines for the treatment of hypertension.
Other prominent vendors in the market are Actelion Pharmaceuticals, Arena Pharmaceuticals, Asahi Kasei, Bayer HealthCare, Bellerophon Therapeutics, Bial, CJ HealthCare, Conatus Pharmaceuticals, Deka Pharmaceuticals, Dong-A ST, Eiger BioPharmaceuticals, Forest Laboratories, Gilead Sciences, HanAll BioPharma, Hanmi Pharmaceutical, Johnson & Johnson, LG Life Sciences, Lung Biotechnology, Lupin Pharmaceuticals, Mast Therapeutics, Merck, Northern Therapeutics, Ono Pharmaceutical,
Pfizer, PhaseBio, Pluristem Therapeutics, Quantum Genomics, Radikal Therapeutics, Reata Pharmaceuticals, Serodus, sigma-tau i.f.r, SteadyMed Therapeutics, Suda, Sun Pharmaceutical Industries, Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, and Yuhan.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Cardiovascular drugs market
PART 06: Overview: Hypertension
PART 07: Epidemiology and economic burden
PART 08: Pipeline portfolio
PART 09: Market landscape
PART 10: Market segmentation by type
PART 11: Market segmentation by drug class
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Appendix
PART 20: Explore Technavio
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.